Abstract 14405: The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Diastolic Filling and Function in Chronic Systolic Heart Failure (COSMIC-HF)

Abstract 14405: The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Diastolic Filling and Function in Chronic Systolic Heart Failure (COSMIC-HF)

IntroductionOmecamtiv mecarbil (OM) is a selective cardiac myosin activator which increases cardiac contractility and systolic ejection time (SET).ObjectiveThe objective of this post-hoc analysis was to determine the effect of chronic therapy with OM on diastolic function in patients with heart fail...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A14405-A14405
Hauptverfasser: Biering-Sørensen, Tor, Teerlink, John R, Minamisawa, Masatoshi, Felker, Gary Michael, McMurray, John J, Malik, Fady, Goldsmith, Steven R, Kurtz, Christopher, Solomon, Scott
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionOmecamtiv mecarbil (OM) is a selective cardiac myosin activator which increases cardiac contractility and systolic ejection time (SET).ObjectiveThe objective of this post-hoc analysis was to determine the effect of chronic therapy with OM on diastolic function in patients with heart failure (HF).MethodsIn the COSMIC-HF trial, 448 patients with stable, symptomatic HF and left ventricular ejection fraction (LVEF)
ISSN:0009-7322
1524-4539
DOI:10.1161/circ.140.suppl_1.14405